Prepandemic Physical Activity Tied to COVID-19 Diagnosis
By Lori Solomon HealthDay Reporter
WEDNESDAY, Feb. 14, 2024 -- Higher prepandemic physical activity (PA) levels are associated with lower odds of developing and being hospitalized for COVID-19, according to a study published online Feb. 13 in JAMA Network Open.
Dennis Muñoz-Vergara, D.V.M., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues examined the association between self-reported prepandemic PA levels and the risk and severity of COVID-19 in older U.S. adults. The analysis included data from three ongoing prospective randomized clinical trials of 61,557 U.S. adults (aged 45 years and older).
The researchers found that when controlling for demographics, body mass index, lifestyle factors, comorbidities, and medications used, those insufficiently active had no significant reduction in infection (odds ratio [OR], 0.96; 95 percent confidence interval [CI], 0.86 to 1.06) or hospitalization (OR, 0.98; 95 percent CI, 0.76 to 1.28) versus inactive individuals. However, participants who were sufficiently active had a significant reduction in infection (OR, 0.90; 95 percent CI, 0.84 to 0.97) and hospitalization (OR, 0.73; 95 percent CI, 0.60 to 0.90). The association with PA showed differences by sex, with only sufficiently active women having decreased odds of SARS-CoV-2 infection (OR, 0.87; 95 percent CI, 0.79 to 0.95).
"Future studies including quantitative control of PA parameters, broader racial and ethnic diversity, and information from other potential confounders (e.g., sleep quality, dietary patterns, access to health care, and preventive behaviors) are warranted," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Further Support and Information on COVID-19
Read this next
Residual Risk Seen for Death, Postacute Sequelae in Third Year After COVID-19 Hospitalization
THURSDAY, June 13, 2024 -- For individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the risks for death and postacute sequelae of COVID-19...
Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response
TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting...
Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms
MONDAY, June 10, 2024 -- A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.